Regeneron announces positive results from phase 3 trial in generalized myasthenia gravis

Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in myasthenia gravis activities of daily living (mg-adl) total score
REGN Ratings Summary
REGN Quant Ranking